The Latest Breaking News from Eli Lilly

The pharma industry's potential for sustained growth is reinforced by an aging population, escalating healthcare demands, and the increase in chronic diseases. Therefore, let’s assess the fundamentals of pharma stocks Eli Lilly (LLY), Johnson & Johnson (JNJ), and Abbvie (ABBV) to determine the most promising choice for the current year….

Eli Lilly (LLY) is showing elevated implied volatility with an IV Percentile of 98%, and that could mean it’s a good time for an iron condor trade.

Eli Lilly's diversified portfolio and high demand for its weight-loss drugs have pushed it to the top of Wall Street's list of top pharma stocks for 2024. Is now the time to buy?

Insulin price caps from Eli Lilly, Novo Nordisk and Sanofi take effect this month.

‘They gain back about half the weight they had originally lost over a one-year period of time,’ professor says

Earlier this month, the FDA approved Eli Lilly's Zepbound, a drug similar to its diabetes drug Mounjaro but specifically advertised for weight loss.

Like many Americans struggling to lose weight, Marissa Montanino felt compelled to try Ozempic or one of the other new so-called "wonder drugs" described as revolutionary in the fight against obesity.

Pfizer shares sank Friday when the drugmaker announced that it was abandoning a twice-daily obesity treatment after more than half the patients in a clinical trial stopped taking it

Zepbound is expected to be available in the U.S. by the end of the year.